List of Figures:
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 16
Figure 4. Europe Small Molecule CDMO Market, 2021-2031, $ mn 19
Figure 5. Impact of COVID-19 on Business 22
Figure 6. Primary Drivers and Impact Factors of Europe Small Molecule CDMO Market 24
Figure 7. Primary Restraints and Impact Factors of Europe Small Molecule CDMO Market 28
Figure 8. Investment Opportunity Analysis 32
Figure 9. Porter’s Fiver Forces Analysis of Europe Small Molecule CDMO Market 35
Figure 10. Breakdown of Europe Small Molecule CDMO Market by Product Type, 2021-2031, % of Revenue 40
Figure 11. Europe Addressable Market Cap in 2022-2031 by Product Type, Value ($ mn) and Share (%) 40
Figure 12. Europe Small Molecule CDMO Market by Product Type: Active Pharmaceutical Ingredients (API), 2021-2031, $ mn 41
Figure 13. Europe Small Molecule CDMO Market by API: Branded Drugs, 2021-2031, $ mn 42
Figure 14. Europe Small Molecule CDMO Market by API: Generic Drugs, 2021-2031, $ mn 43
Figure 15. Europe Small Molecule CDMO Market by Product Type: Finished Dosage Formulations (FDF), 2021-2031, $ mn 44
Figure 16. Europe Small Molecule CDMO Market by FDF: Oral Solid Drugs, 2021-2031, $ mn 46
Figure 17. Europe Small Molecule CDMO Market by FDF: Injectable Drugs, 2021-2031, $ mn 47
Figure 18. Europe Small Molecule CDMO Market by FDF: Semi-solid or Liquid Drugs, 2021-2031, $ mn 48
Figure 19. Europe Small Molecule CDMO Market by FDF: Other FDFs, 2021-2031, $ mn 49
Figure 20. Breakdown of Europe Small Molecule CDMO Market by Service Type, 2021-2031, % of Sales Revenue 51
Figure 21. Europe Addressable Market Cap in 2022-2031 by Service Type, Value ($ mn) and Share (%) 51
Figure 22. Europe Small Molecule CDMO Market by Service Type: Preclinical Use, 2021-2031, $ mn 52
Figure 23. Europe Small Molecule CDMO Market by Service Type: Clinical Use, 2021-2031, $ mn 53
Figure 24. Europe Small Molecule CDMO Market by Clinical Use: Phase I, 2021-2031, $ mn 55
Figure 25. Europe Small Molecule CDMO Market by Clinical Use: Phase II, 2021-2031, $ mn 56
Figure 26. Europe Small Molecule CDMO Market by Clinical Use: Phase III, 2021-2031, $ mn 57
Figure 27. Europe Small Molecule CDMO Market by Clinical Use: Phase IV, 2021-2031, $ mn 58
Figure 28. Europe Small Molecule CDMO Market by Service Type: Commercial Use, 2021-2031, $ mn 59
Figure 29. Breakdown of Europe Small Molecule CDMO Market by Customer Type, 2021-2031, % of Sales Revenue 61
Figure 30. Europe Addressable Market Cap in 2022-2031 by Customer Type, Value ($ mn) and Share (%) 61
Figure 31. Europe Small Molecule CDMO Market by Customer Type: Pharmaceutical Firms, 2021-2031, $ mn 62
Figure 32. Europe Small Molecule CDMO Market by Customer Type: Biotechnology Firms, 2021-2031, $ mn 63
Figure 33. Breakdown of Europe Small Molecule CDMO Market by Therapeutic Area, 2021-2031, % of Revenue 65
Figure 34. Europe Addressable Market Cap in 2022-2031 by Therapeutic Area, Value ($ mn) and Share (%) 65
Figure 35. Europe Small Molecule CDMO Market by Therapeutic Area: Infectious Diseases, 2021-2031, $ mn 66
Figure 36. Europe Small Molecule CDMO Market by Therapeutic Area: Oncology, 2021-2031, $ mn 67
Figure 37. Europe Small Molecule CDMO Market by Therapeutic Area: Ophthalmology, 2021-2031, $ mn 68
Figure 38. Europe Small Molecule CDMO Market by Therapeutic Area: Cardiovascular Disorders, 2021-2031, $ mn 69
Figure 39. Europe Small Molecule CDMO Market by Therapeutic Area: Central Nervous System, 2021-2031, $ mn 70
Figure 40. Europe Small Molecule CDMO Market by Therapeutic Area: Respiratory Disorders, 2021-2031, $ mn 71
Figure 41. Europe Small Molecule CDMO Market by Therapeutic Area: Metabolic Diseases, 2021-2031, $ mn 72
Figure 42. Europe Small Molecule CDMO Market by Therapeutic Area: Other Therapeutic Areas, 2021-2031, $ mn 73
Figure 43. Breakdown of European Small Molecule CDMO Market by Country, 2021 and 2031, % of Revenue 75
Figure 44. Contribution to Europe 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 76
Figure 45. Small Molecule CDMO Market in Germany, 2021-2031, $ mn 77
Figure 46. Small Molecule CDMO Market in U.K., 2021-2031, $ mn 79
Figure 47. Small Molecule CDMO Market in France, 2021-2031, $ mn 81
Figure 48. Small Molecule CDMO Market in Spain, 2021-2031, $ mn 83
Figure 49. Small Molecule CDMO Market in Italy, 2021-2031, $ mn 85
Figure 50. Small Molecule CDMO Market in Netherlands, 2021-2031, $ mn 87
Figure 51. Small Molecule CDMO Market in Rest of Europe, 2021-2031, $ mn 89
Figure 52. Growth Stage of Europe Small Molecule CDMO Industry over the Forecast Period 91
Europe small molecule contract development and manufacturing organization (CDMO) market was valued at $ 17,340.6 million in 2021 and will grow by 6.2% annually over 2021-2031, driven by the increasing demand for small molecule medicines and therapies, a rising demand for cost control in drug development, the increasing incidence of disease, and rising healthcare expenditures. Highlighted with 34 tables and 52 figures, this 111-page report “Europe Small Molecule Contract Development and Manufacturing Organization (CDMO) Market 2021-2031 by Product Type (API, FDF), Service Type (Preclinical, Clinical, Commercial), Customer Type (Pharmaceutical Firms, Biotechnology Firms), Therapeutic Area (Infectious Diseases, Oncology, Ophthalmology, Cardiovascular Disorders, Central Nervous System, Respiratory Disorders, Metabolic Diseases), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe small molecule contract development and manufacturing organization (CDMO) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Europe small molecule contract development and manufacturing organization (CDMO) market in every aspect of the classification from perspectives of Product Type, Service Type, Customer Type, Therapeutic Area, and Country. Based on Product Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Active Pharmaceutical Ingredients (API) o Branded Drugs o Generic Drugs • Finished Dosage Formulations (FDF) o Oral Solid Drugs o Injectable Drugs o Semi-solid or Liquid Drugs o Other FDFs Based on Service Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Preclinical Use • Clinical Use o Phase I o Phase II o Phase III o Phase IV • Commercial Use By Customer Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Pharmaceutical Firms • Biotechnology Firms By Therapeutic Area, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Infectious Diseases • Oncology • Ophthalmology • Cardiovascular Disorders • Central Nervous System • Respiratory Disorders • Metabolic Diseases • Other Therapeutic Areas Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Netherlands • Rest of Europe (further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product Type, Service Type and Therapeutic Area over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Boehringer Ingelheim Cambrex Corporation Catalent Cipla Covance Inc. Lonza Group Ltd. Medley Pharmaceuticals NatcoPharma Patheon (Thermo Fisher Scientific, Inc.) Piramal Pharma Solutions RedHillBiopharma Siegfried Holding AG STA Pharmaceutical Sun Pharmaceutical Teva (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More